Alzheimer's Society responds to Alzheimer's disease treatment priority review
This marks another crucial step forward in the development of the first ever treatment to slow down the progression of Alzheimer’s disease
Fiona Carragher, Director of Research and Influencing at Alzheimer’s Society said:
“This marks another crucial step forward in the development of the first ever treatment to slow down the progression of Alzheimer’s disease. This journey began, in part, with Alzheimer’s Society’s funded pivotal genetic discovery, which identified the first Alzheimer’s gene and ultimately the development of anti-amyloid drugs.
“While news that the application to the US regulatory authorities has been fast-tracked should certainly give people affected by dementia a boost - this is a world first for dementia research - the journey is not yet complete.
Currently treatment options are limited so people may ask ‘What is there to be lost?’ but it’s critical we fully understand the impact and safety of this drug which will now be down to the US Food and Drug Administration to determine.
“This important milestone towards treating this devastating disease is one we never would have achieved without the efforts of the dedicated, passionate research community and funders like Alzheimer’s Society who make dementia research possible.
It’s vital the UK government provides financial support to medical research charities so that the glimmer of hope provided by research is not put out by the COVID-19 pandemic.”
